We have identified you may not be viewing TRAVAX optimally because the browser you are using is unsupported - click here.
We have identified you may not be viewing TRAVAX optimally because the browser you are using is unsupported - click here.
Supplies of UK licensed BCG vaccine from Statens Serum Institute (SSI) continue to be delayed due to manufacturing issues. Public Health England (responsible for procuring BCG vaccine on behalf of Scotland and the other UK nations) continue to advise that the current stated shelf life of SSI BCG vaccine batch 114022A (the most recently distributed SSI BCG vaccine) should be extended by 6 months from 29 February 2016 to 31 August 2016.
Public Health England has secured an alternative BCG vaccine supply from InterVax Ltd that is manufactured by BB-NCIPD Ltd. Intervax BCG vaccine is currently unlicensed in the UK (meaning it does not have valid marketing authorisation in UK) and is therefore being supplied in accordance with medicines legislation which allows an unlicensed medicine to be supplied when a licensed alternative is not available. Although unlicensed in the UK, Intervax BCG vaccine is a WHO (World Health Organisation) prequalified vaccine meaning it can be used around the world for immunisation against TB. InterVax BCG vaccine can be used for the national BCG immunisation programme until SSI is able to resume deliveries (expected in 2017).
Remaining doses of SSI BCG vaccine lot 114022A should continue to be used until the recommended date of 31 August 2016, and in preference to the alternative unlicensed InterVax BCG vaccine.
Initially, a limited volume of InterVax BCG vaccine will be available to order through ImmForm, alongside remaining stock of SSI BCG vaccine. Please check the ImmForm website for the latest information available.
